365telugu.com online news,Hyderabad, October 24th, 2025:AIG Hospitals, in partnership with GenepoweRx, has launched India’s first cost-effective Pharmacogenomics Test, a groundbreaking initiative to personalize medical prescriptions based on an individual’s genetic profile. This transformative step in precision medicine aims to enhance treatment efficacy and patient safety across India.
A collaborative study involving 2,000 patients revealed that nearly 30% were prescribed medications misaligned with their genetic makeup, resulting in suboptimal treatment outcomes or preventable side effects.
This soon-to-be-published research underscores the urgent need for personalized medicine in India, where a one-size-fits-all approach to prescriptions remains prevalent.
The Pharmacogenomics Test analyzes an individual’s genetic code to predict their response to medications commonly used for conditions such as heart disease, diabetes, cancer, gastrointestinal disorders, neurological and psychiatric conditions, and pain management. By tailoring prescriptions to genetic profiles, the test minimizes adverse reactions and optimizes therapeutic outcomes.
Dr. D Nageshwar Reddy, Chairman of AIG Hospitals, stated: “Our findings show that one in three patients may be taking genetically unsuitable medications, impacting both safety and healthcare costs.
At AIG Hospitals, we are committed to making precision medicine accessible to every Indian through this affordable test, replacing trial-and-error prescribing with evidence-based care. This initiative also lays the groundwork for large-scale genomic research in India.”
The test, which is a one-time procedure due to the static nature of a person’s genetic profile, provides patients with a personalized report booklet. This report can be shared with any doctor worldwide, ensuring all future prescriptions are customized to the patient’s genetic makeup.
What sets this initiative apart is its affordability. While similar tests cost approximately ₹80,000 in Western countries, AIG Hospitals offers it at just ₹5,000, making world-class precision medicine accessible to Indian patients at a fraction of the global cost.
In collaboration with GenepoweRx, a leader in genomics and AI-driven precision medicine, the test leverages the proprietary SIGMA-ML platform. This platform uses advanced algorithms and next-generation sequencing to deliver physician-friendly reports.
Dr. Kalyan Uppaluri, Managing Director of GenepoweRx, commented: “Partnering with AIG Hospitals allows us to integrate cutting-edge pharmacogenomic testing into routine clinical practice, enabling doctors to prescribe safer and more effective medications.”
The test results are seamlessly integrated into AIG Hospitals’ electronic medical record (EMR) system, providing doctors with immediate access to genomic insights for informed prescribing decisions.
This launch represents a pivotal shift in Indian healthcare, moving from standardized prescriptions to personalized medicine. By combining clinical expertise with genomic intelligence, AIG Hospitals aims to reduce adverse drug reactions, improve recovery rates, and ensure safer, more effective treatments for millions.
For more details, AIG Hospitals is hosting a virtual Q&A session with Dr. D Nageshwar Reddy on October 23, 2025, at 1:00 PM to address queries about this initiative.